{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:26:32Z","timestamp":1780957592028,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10147-025-02714-4","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:07:46Z","timestamp":1741432066000},"page":"993-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401)"],"prefix":"10.1007","volume":"30","author":[{"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-782X","authenticated-orcid":false,"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Urologic Oncology Study Group of Japan Clinical Oncology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2714_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial. Eur Urol 66:243\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.011","journal-title":"Eur Urol"},{"key":"2714_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jama.2018.0587","volume":"319","author":"AU Kishan","year":"2018","unstructured":"Kishan AU, Cook RR, Ciezki JP et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer. JAMA 319:896\u2013905. https:\/\/doi.org\/10.1001\/jama.2018.0587","journal-title":"JAMA"},{"key":"2714_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396:1413\u20131421. https:\/\/doi.org\/10.1016\/S0140-6736(20)31553-1","journal-title":"Lancet"},{"key":"2714_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331\u20131340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3","journal-title":"Lancet Oncol"},{"key":"2714_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21:1341\u20131352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X","journal-title":"Lancet Oncol"},{"key":"2714_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.eururo.2019.11.023","volume":"77","author":"A Yokomizo","year":"2020","unstructured":"Yokomizo A, Wakabayashi M, Satoh T et al (2020) Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, Phase 3 trial (JCOG0401)\u2020. Eur Urol 77:689\u2013698. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.023","journal-title":"Eur Urol"},{"key":"2714_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"2714_CR8","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760\u20132769. https:\/\/doi.org\/10.1001\/jama.299.23.2760","journal-title":"JAMA"},{"key":"2714_CR9","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 70:926\u2013937","journal-title":"Eur Urol"},{"key":"2714_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","volume":"73","author":"DE Spratt","year":"2018","unstructured":"Spratt DE, Dess RT, Zumsteg ZS et al (2018) A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol 73:156\u2013165. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.027","journal-title":"Eur Urol"},{"key":"2714_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jjco\/hyi007","volume":"35","author":"A Yokomizo","year":"2005","unstructured":"Yokomizo A, Kawamoto H, Nihei K et al (2005) Randomized controlled trial to evaluate radiotherapy +\/\u2212 endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 35:34\u201336. https:\/\/doi.org\/10.1093\/jjco\/hyi007","journal-title":"Jpn J Clin Oncol"},{"key":"2714_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2011.10.077","volume":"84","author":"A Goenka","year":"2012","unstructured":"Goenka A, Magsanoc JM, Pei X et al (2012) Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84:112\u2013118. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.10.077","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2714_CR13","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035\u20132041. https:\/\/doi.org\/10.1200\/JCO.2006.08.9607","journal-title":"J Clin Oncol"},{"key":"2714_CR14","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar RD, Agrawal S, Gao T et al (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 34:3648\u20133654. https:\/\/doi.org\/10.1200\/JCO.2016.67.9647","journal-title":"J Clin Oncol"},{"key":"2714_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.euo.2021.04.011","volume":"5","author":"SR Campbell","year":"2022","unstructured":"Campbell SR, Tom MC, Agrawal S et al (2022) Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy. Eur Urol Oncol 5:304\u2013313. https:\/\/doi.org\/10.1016\/j.euo.2021.04.011","journal-title":"Eur Urol Oncol"},{"key":"2714_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jjco\/hyi113","volume":"35","author":"S Naito","year":"2005","unstructured":"Naito S (2005) Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 35:365\u2013374. https:\/\/doi.org\/10.1093\/jjco\/hyi113","journal-title":"Jpn J Clin Oncol"},{"key":"2714_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403\u2013417. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049","journal-title":"Eur Urol"},{"key":"2714_CR18","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP, Ferdinandus J, Czernin J et al (2020) Impact of 68ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med 61:1793\u20131799. https:\/\/doi.org\/10.2967\/jnumed.120.242180","journal-title":"J Nucl Med"},{"key":"2714_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14748","volume":"6","author":"C Zamboglou","year":"2023","unstructured":"Zamboglou C, Peeken JC, Janbain A et al (2023) Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6:e2314748. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14748","journal-title":"JAMA Netw Open"},{"key":"2714_CR20","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1007\/s00520-022-06876-z","volume":"30","author":"C James","year":"2022","unstructured":"James C, Brunckhorst O, Eymech O et al (2022) Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review. Support Care Cancer 30:5577\u20135589. https:\/\/doi.org\/10.1007\/s00520-022-06876-z","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02714-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:04:16Z","timestamp":1745301856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02714-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02714-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akira Yokomizo received honoraria from Astra Zeneca and Takeda. Takahiro Kimura received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Sanofi, and Takeda. Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer Yakuhin. Toyonori Tsuzuki reports honoraria for lectures from AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Janssen Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Pfizer. Masashi Kato received honoraria from AstraZeneca and Janssen Pharmaceutical; research funding from AstraZeneca; research funding from Astellas Pharma. Masatoshi Eto reports honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Eisai, Janssen Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical; research funding from Bristol Myers Squibb, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical. Hiroshi Kitamura received honoraria from Astellas, AstraZeneca, Bristol Myers Squibb, Merck Biopharma, MSD, Sanofi, and Takeda; research funding from MSD. Mikio Sugimoto received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Pfizer, Takeda, Nippon Shinyaku.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}